CLINICAL SIGNIFICANCE OF ANTI–DOUBLE-STRANDED DNA ANTIBODIES DETECTED BY A SOLID PHASE ENZYME IMMUNOASSAY
✍ Scribed by Thomas E. Miller; Robert G. Lahita; Vincent J. Zarro; Joanne Macwilliam; David Koffler
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 752 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
A solid phase enzyme immunoassay (EIA) detected anti‐double‐stranded (ds) DNA antibodies in 88% of sera from patients classified clinically as having active systemic lupus erythematosus (SLE) without renal symptoms and 93% with renal disease. Fifty‐six percent of sera from patients with inactive SLE were EIA positive for anti‐dsDNA antibodies. The EIA had a sensitivity and specificity comparable to radioimmunoassay (RIA) and hemagglutination for patients with active SLE with or without renal disease, but it detected anti‐dsDNA antibodies more frequently in patients with inactive SLE than the latter procedures. Precipitating antibodies detected by counterimmunoelectrophoresis (CIE) were less common in patients with renal disease (23% incidence) than clinically active patients without renal disease (79% incidence). Twenty‐four SLE sera with elevated levels of CIq binding showed a 96% concordance for a positive EIA for anti‐dsDNA antibodies in contrast to 66% concordance by RIA or hemagglutination. These findings suggest that the EIA is a sensitive and specific method for detection and measurement of anti‐dsDNA antibodies. Several clinical applications of the EIA are discussed.